Evidence map›Paper›PMID 34475387›Full record

ArticleNature communications2021

Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding.

Kevin Wittwer, Danielle E Anderson, Kristin Pfeffermann, Robert M Cox, Josef D Wolf, Sabine Santibanez, Annette Mankertz, Roland Plesker, Zachary M Sticher, Alexander A Kolkykhalov and 4 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Structural insights into measles virus RNA synthesis regulation and pan-paramyxoviral polymerase inhibition by ERDRP-0519.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024
    Review
  9. Article
  10. Review
  11. Article
  12. Anno 2021: Which antivirals for the coming decade?Annual reports in medicinal chemistry · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Kevin WittwerVeterinary Medicine Division, Paul-Ehrlich-Institute, Langen, Germany.
Danielle E AndersonProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
Kristin PfeffermannVeterinary Medicine Division, Paul-Ehrlich-Institute, Langen, Germany.
Robert M CoxInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.ORCID 0000-0003-0620-1674
Josef D WolfInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Sabine SantibanezWHO European Regional Reference Laboratory for Measles and Rubella, Robert Koch-Institute, Berlin, Germany.
Annette MankertzWHO European Regional Reference Laboratory for Measles and Rubella, Robert Koch-Institute, Berlin, Germany.
Roland PleskerVeterinary Medicine Division, Paul-Ehrlich-Institute, Langen, Germany.
Zachary M SticherEmory Institute for Drug Development, Emory University, Atlanta, GA, USA.ORCID 0000-0002-7022-1410
Alexander A KolkykhalovEmory Institute for Drug Development, Emory University, Atlanta, GA, USA.
Michael G NatchusEmory Institute for Drug Development, Emory University, Atlanta, GA, USA.
Christian K PfallerVeterinary Medicine Division, Paul-Ehrlich-Institute, Langen, Germany. Christian.Pfaller@pei.de.ORCID 0000-0003-3302-0780
Richard K PlemperInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA. rplemper@gsu.edu.ORCID 0000-0003-2034-2107
Veronika von MesslingVeterinary Medicine Division, Paul-Ehrlich-Institute, Langen, Germany.
Paul Ehrlich Institut · DEEmory University · USGeorgia State University · USRobert Koch Institute · DEBundesministerium für Forschung, Technologie und Raumfahrt · DEDuke-NUS Medical School · SG

Funding

Identification and Pre-Clinical Evaluation of Measles Virus InhibitorsR01AI071002 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2006 to 2022
$6.6M
Polymerase Inhibitors of Respiratory Syncytial VirusR01AI153400 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2020 to 2024
$3.7M
NIAID NIH HHS R01 AI071002NIAID NIH HHS R01 AI153400
6 · The paper itself

Abstract

Measles virus (MeV) is a highly contagious pathogen that enters the human host via the respiratory route. Besides acute pathologies including fever, cough and the characteristic measles rash, the infection of lymphocytes leads to substantial immunosuppression that can exacerbate the outcome of infections with additional pathogens. Despite the availability of effective vaccine prophylaxis, measles outbreaks continue to occur worldwide. We demonstrate that prophylactic and post-exposure therapeutic treatment with an orally bioavailable small-molecule polymerase inhibitor, ERDRP-0519, prevents measles disease in squirrel monkeys (Saimiri sciureus). Treatment initiation at the onset of clinical signs reduced virus shedding, which may support outbreak control. Results show that this clinical candidate has the potential to alleviate clinical measles and augment measles virus eradication.

Indexed as

AnimalsDrug Evaluation, PreclinicalEnzyme InhibitorsImmune ToleranceImmunity, HumoralMeaslesMeasles virusMorpholinesPiperidinesPyrazolesRNA-Dependent RNA PolymeraseSaimiriVirus ReplicationVirus SheddingEnzyme InhibitorsERDRP-0519MorpholinesPiperidinesPyrazolesRNA-Dependent RNA Polymerase

Identifiers

PMID34475387
PMCPMC8413292
OpenAlexW3198481493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.